- Home
- FENG vs RAPT Comparison
FENG vs RAPT Comparison
Compare FENG & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- RAPT
- Stock Information
- Founded
- FENG 1998
- RAPT 2015
- Country
- FENG China
- RAPT United States
- Employees
- FENG N/A
- RAPT N/A
- Industry
- FENG Broadcasting
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- FENG Industrials
- RAPT Health Care
- Exchange
- FENG Nasdaq
- RAPT Nasdaq
- Market Cap
- FENG 29.7M
- RAPT 30.8M
- IPO Year
- FENG 2011
- RAPT 2019
- Fundamental
- Price
- FENG $2.56
- RAPT $0.89
- Analyst Decision
- FENG
- RAPT Hold
- Analyst Count
- FENG 0
- RAPT 10
- Target Price
- FENG N/A
- RAPT $5.00
- AVG Volume (30 Days)
- FENG 7.4K
- RAPT 386.3K
- Earning Date
- FENG 11-12-2024
- RAPT 11-12-2024
- Dividend Yield
- FENG N/A
- RAPT N/A
- EPS Growth
- FENG N/A
- RAPT N/A
- EPS
- FENG N/A
- RAPT N/A
- Revenue
- FENG $99,426,474.00
- RAPT N/A
- Revenue This Year
- FENG N/A
- RAPT N/A
- Revenue Next Year
- FENG N/A
- RAPT N/A
- P/E Ratio
- FENG N/A
- RAPT N/A
- Revenue Growth
- FENG N/A
- RAPT N/A
- 52 Week Low
- FENG $1.20
- RAPT $0.81
- 52 Week High
- FENG $4.15
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- FENG 48.68
- RAPT 36.23
- Support Level
- FENG $2.14
- RAPT $0.84
- Resistance Level
- FENG $2.70
- RAPT $1.18
- Average True Range (ATR)
- FENG 0.22
- RAPT 0.10
- MACD
- FENG 0.02
- RAPT 0.01
- Stochastic Oscillator
- FENG 60.87
- RAPT 17.00
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.